Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women.[1] It is intended for use by mouth.[1] As of December 2017, it is in phase III clinical trials for this indication.[1]

Acolbifene/prasterone
Combination of
AcolbifeneSelective estrogen receptor modulator
PrasteroneAndrogen
Clinical data
Trade namesFemivia (tentative)
Other namesPrasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene
Routes of
administration
By mouth

See also

edit

References

edit
  1. ^ a b c "Acolbifene/Prasterone - Endoceutics - AdisInsight".
edit